European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees

Rudi Dierckx; Ken Herrmann; Roland Hustinx; Michael Lassman; Wolfgang Wadsak; Jolanta Kunikowska

doi:10.1007/s00259-022-06011-4

European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees

Rudi Dierckx, Ken Herrmann, Roland Hustinx, Michael Lassman, Wolfgang Wadsak, Jolanta Kunikowska^*

^*Bijbehorende auteur voor dit werk

Onderzoeksoutput › Academic › peer review

1 Citaat (Scopus)

Originele taal-2	English
Pagina's (van-tot)	1-3
Aantal pagina's	3
Tijdschrift	European Journal of Nuclear Medicine and Molecular Imaging
Volume	50
Vroegere onlinedatum	17-okt.-2022
DOI's	https://doi.org/10.1007/s00259-022-06011-4
Status	Published - dec.-2022

Toegang tot document

10.1007/s00259-022-06011-4

Handle.net

Permanente koppeling

Document onder embargo

European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees
Final publisher's version, 377 KB
Licentie: Taverne
Embargo eindigt: 17/04/2023
Kopie aanvragen

1 Citaties
1 Erratum

Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 50, 1, (1-3), 10.1007/s00259-022-06011-4)
Dierckx, R., Herrmann, K., Hustinx, R., Lassmann, M., Wadsak, W. & Kunikowska, J., 14-nov.-2022, In: European Journal of Nuclear Medicine and Molecular Imaging. 1 blz.
Onderzoeksoutput

Citeer dit

@article{3b9459bd1b7146f9b22af98982200831,

title = "European Association of Nuclear Medicine (EANM) response to the proposed ASTRO{\textquoteright}s framework for radiopharmaceutical therapy curriculum development for trainees",

author = "Rudi Dierckx and Ken Herrmann and Roland Hustinx and Michael Lassman and Wolfgang Wadsak and Jolanta Kunikowska",

note = "Funding Information: WW has received research grants from ITM S.E., Scintomics, EZAG, Novo Nordisk (all institutional fees), consultancy fees from GE Healthcare (personal fees) and is a part-time employee of CBmed GmbH, Graz, Austria, and a founder and co-owner of MINUTE medical GmbH, Vienna, Austria. Funding Information: KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen, outside the submitted work. ",

year = "2022",

month = dec,

doi = "10.1007/s00259-022-06011-4",

language = "English",

volume = "50",

pages = "1--3",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "SPRINGER",

}

TY - JOUR

T1 - European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees

AU - Dierckx, Rudi

AU - Herrmann, Ken

AU - Hustinx, Roland

AU - Lassman, Michael

AU - Wadsak, Wolfgang

AU - Kunikowska, Jolanta

N1 - Funding Information: WW has received research grants from ITM S.E., Scintomics, EZAG, Novo Nordisk (all institutional fees), consultancy fees from GE Healthcare (personal fees) and is a part-time employee of CBmed GmbH, Graz, Austria, and a founder and co-owner of MINUTE medical GmbH, Vienna, Austria. Funding Information: KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen, outside the submitted work.

PY - 2022/12

Y1 - 2022/12

U2 - 10.1007/s00259-022-06011-4

DO - 10.1007/s00259-022-06011-4

M3 - Editorial

C2 - 36251026

AN - SCOPUS:85139966230

VL - 50

SP - 1

EP - 3

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -

European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees

Toegang tot document

Handle.net

Document onder embargo

Onderzoekersoutput

Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 50, 1, (1-3), 10.1007/s00259-022-06011-4)

Citeer dit